Byetta®
Manufacturer:
Amylin Pharmaceuticals, Inc. & Eli Lilly & Co.
More Information
|
The FDA is alerting health care professionals that
Byetta® may be associated with acute pancreatitis in some patients.
Byetta® is administered by a twice a day injection to treat type two
diabetes. More than 700,000 patients have used the drug since it was
released in 2005.
The FDA has reviewed 30 reports of individuals taking
Byetta® and developed acute pancreatitis. 21 of those
patients were hospitalized, five of them with serious complications.
22 of these individuals improved after discontinuing the drug.
Symptoms of acute pancreatitis are persistent and
severe abdominal pain possibly accompanied by vomiting.
If you or someone you know has sustained acute
pancreatitis or other damages while taking Byetta®, please contact us to
discuss your rights,
www.816LAWFIRM.com or
call us toll-free at 1-800-305-7552.
Call Peterson & Associates today &
Click Here.
|
| Byetta |
For more information:
Pharmaceutical Litigation
Prescription
Injury FAQs
Pharmaceutical Legal Glossary
Recent Byetta Headlines
>> Novartis to sell $5B in bonds for Alcon buy; Abbott to buy Facet Biote... - Wed, 10 Mar 2010
>> Upgrades & Downgrades: Bed Bath & Beyond Looking Tired - Minyanville.c... - Thu, 11 Mar 2010
>> Weather delays US FDA action on long-acting Byetta - Reuters... - Thu, 25 Feb 2010
>> Taspoglutide may have the highest potential of sales amongst GLP-1 - G... - Wed, 10 Mar 2010
>> PDUFA date for Exenatide Approaching (Nasdaq:AMLN), (NYSE:LLY) - FavSt... - Thu, 11 Mar 2010
|
